Latest News: Proscia Receives FDA 510(k) Clearance For Concentriq AP-DxREAD THE PRESS RELEASE

PathGroup Moving Toward 100% Digital Pathology

By Author Proscia | September 21, 2023

Laboratory Economics‘ Jondavid Klipp spoke with Concentriq Dx* user Derek Welch, MD, Chief Medical Officer and Executive Vice-President at PathGroup. In the Q&A, Dr. Welch speaks to PathGroup’s progress in achieving 100% digitization and the benefits it has seen thus far. From helping pathologists to move more quickly from slide to slide and between cases to speeding up turnaround time and enabling almost real-time sharing of cases, digital pathology has driven meaningful efficiencies for PathGroup.

*Concentriq Dx is CE-marked under IVDR and is available for primary diagnosis in the US under the COVID-19 enforcement policy for remote pathology devices.

Our website uses cookies. By using this site, you agree to its use of cookies.